Cargando…
Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications
Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical act...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395214/ https://www.ncbi.nlm.nih.gov/pubmed/32738903 http://dx.doi.org/10.1186/s12906-020-03033-z |
_version_ | 1783565367058104320 |
---|---|
author | Taheri, Yasaman Suleria, Hafiz Ansar Rasul Martins, Natália Sytar, Oksana Beyatli, Ahmet Yeskaliyeva, Balakyz Seitimova, Gulnaz Salehi, Bahare Semwal, Prabhakar Painuli, Sakshi Kumar, Anuj Azzini, Elena Martorell, Miquel Setzer, William N. Maroyi, Alfred Sharifi-Rad, Javad |
author_facet | Taheri, Yasaman Suleria, Hafiz Ansar Rasul Martins, Natália Sytar, Oksana Beyatli, Ahmet Yeskaliyeva, Balakyz Seitimova, Gulnaz Salehi, Bahare Semwal, Prabhakar Painuli, Sakshi Kumar, Anuj Azzini, Elena Martorell, Miquel Setzer, William N. Maroyi, Alfred Sharifi-Rad, Javad |
author_sort | Taheri, Yasaman |
collection | PubMed |
description | Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials. |
format | Online Article Text |
id | pubmed-7395214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73952142020-08-03 Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications Taheri, Yasaman Suleria, Hafiz Ansar Rasul Martins, Natália Sytar, Oksana Beyatli, Ahmet Yeskaliyeva, Balakyz Seitimova, Gulnaz Salehi, Bahare Semwal, Prabhakar Painuli, Sakshi Kumar, Anuj Azzini, Elena Martorell, Miquel Setzer, William N. Maroyi, Alfred Sharifi-Rad, Javad BMC Complement Med Ther Review Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. Myricetin is commonly found in plants and their antimicrobial and antioxidant activities is well demonstrated. One of its beneficial biological effects is the neuroprotective activity, showing preclinical activities on Alzheimer, Parkinson, and Huntington diseases, and even in amyotrophic lateral sclerosis. Also, myricetin has revealed other biological activities, among them as antidiabetic, anticancer, immunomodulatory, cardiovascular, analgesic and antihypertensive. However, few clinical trials have been performed using myricetin as nutraceutical. Thus, this review provides new insights on myricetin preclinical pharmacological activities, and role in selected clinical trials. BioMed Central 2020-08-01 /pmc/articles/PMC7395214/ /pubmed/32738903 http://dx.doi.org/10.1186/s12906-020-03033-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Taheri, Yasaman Suleria, Hafiz Ansar Rasul Martins, Natália Sytar, Oksana Beyatli, Ahmet Yeskaliyeva, Balakyz Seitimova, Gulnaz Salehi, Bahare Semwal, Prabhakar Painuli, Sakshi Kumar, Anuj Azzini, Elena Martorell, Miquel Setzer, William N. Maroyi, Alfred Sharifi-Rad, Javad Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
title | Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
title_full | Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
title_fullStr | Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
title_full_unstemmed | Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
title_short | Myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
title_sort | myricetin bioactive effects: moving from preclinical evidence to potential clinical applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395214/ https://www.ncbi.nlm.nih.gov/pubmed/32738903 http://dx.doi.org/10.1186/s12906-020-03033-z |
work_keys_str_mv | AT taheriyasaman myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT suleriahafizansarrasul myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT martinsnatalia myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT sytaroksana myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT beyatliahmet myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT yeskaliyevabalakyz myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT seitimovagulnaz myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT salehibahare myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT semwalprabhakar myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT painulisakshi myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT kumaranuj myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT azzinielena myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT martorellmiquel myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT setzerwilliamn myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT maroyialfred myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications AT sharifiradjavad myricetinbioactiveeffectsmovingfrompreclinicalevidencetopotentialclinicalapplications |